JERSEY CITY, N.J., April 7, 2015 /PRNewswire/ -- TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced the availability of Convert, a free online clinical trial data conversion service. The complimentary service enables users to quickly and efficiently reuse clinical trial results data that was previously reported to the U.S. registry (clinicaltrials.gov) and convert it to the appropriate format for submission to the European registry (EudraCT).
Clinical trial sponsors face a looming deadline for reporting results in Europe. For eligible clinical trials that ended between July 21, 2013 and July 21, 2014, sponsors are required to post results by July 21, 2015. The data entry burden for only one study is significant and many sponsors have numerous study results to report. Sponsors can gain access to the free conversion service from the TrialScope website at convert.trialscope.com.
TrialScope's Chief Strategy Officer, Thomas Wicks, commented, "TrialScope's complimentary EudraCT conversion service will provide sponsors with an opportunity to maintain compliance while simplifying the effort to do so. The service immediately reduces the data entry burden by as much as 85% for clinical trial results disclosures."
Early feedback from users who previewed the service was very positive with one top pharma team rating the service 10 out of 10 for ease of use and speed. Another team estimated that they would save 5-8 hours per study on data entry alone using TrialScope's Convert service.
Mike Forgash, CEO, TrialScope, added, "Our free EudraCT conversion service will help clinical trial sponsors realize time and resource savings not only by alleviating redundant data entry, but also by leveraging the quality assurance and review processes for data that has already been approved for disclosure in the U.S. The conversion will also ensure alignment of the data across registries, which is a significant compliance challenge for most global sponsors."
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.